Economic  ||| S:0 E:9 ||| JJ
aspects  ||| S:9 E:17 ||| NNS
of  ||| S:17 E:20 ||| IN
sublingual  ||| S:20 E:31 ||| FW
immunotherapy  ||| S:31 E:45 ||| FW
Allergic  ||| S:45 E:54 ||| FW
rhinitis  ||| S:54 E:63 ||| FW
and  ||| S:63 E:67 ||| CC
asthma  ||| S:67 E:74 ||| NNS
have  ||| S:74 E:79 ||| VBP
a  ||| S:79 E:81 ||| DT
very  ||| S:81 E:86 ||| RB
high  ||| S:86 E:91 ||| JJ
prevalence  ||| S:91 E:102 ||| NN
and  ||| S:102 E:106 ||| CC
constitute  ||| S:106 E:117 ||| VB
a  ||| S:117 E:119 ||| DT
health  ||| S:119 E:126 ||| NN
problem  ||| S:126 E:134 ||| NN
with  ||| S:134 E:139 ||| IN
a  ||| S:139 E:141 ||| DT
relevant  ||| S:141 E:150 ||| JJ
burden  ||| S:150 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
disease ||| S:160 E:167 ||| NN
,  ||| S:167 E:169 ||| ,
concerning  ||| S:169 E:180 ||| VBG
medical  ||| S:180 E:188 ||| JJ
and  ||| S:188 E:192 ||| CC
economical  ||| S:192 E:203 ||| JJ
issues ||| S:203 E:209 ||| NNS
.  ||| S:209 E:211 ||| .
Among  ||| S:211 E:217 ||| IN
the  ||| S:217 E:221 ||| DT
treatments  ||| S:221 E:232 ||| NNS
of  ||| S:232 E:235 ||| IN
allergy ||| S:235 E:242 ||| NN
,  ||| S:242 E:244 ||| ,
specific  ||| S:244 E:253 ||| JJ
immunotherapy  ||| S:253 E:267 ||| NNS
( ||| S:267 E:268 ||| -LRB-
IT ||| S:268 E:270 ||| PRP
)  ||| S:270 E:272 ||| -RRB-
has  ||| S:272 E:276 ||| VBZ
the  ||| S:276 E:280 ||| DT
capacity  ||| S:280 E:289 ||| NN
to  ||| S:289 E:292 ||| TO
favourably  ||| S:292 E:303 ||| VB
alter  ||| S:303 E:309 ||| VB
the  ||| S:309 E:313 ||| DT
natural  ||| S:313 E:321 ||| JJ
history  ||| S:321 E:329 ||| NN
of  ||| S:329 E:332 ||| IN
the  ||| S:332 E:336 ||| DT
disease  ||| S:336 E:344 ||| NN
both  ||| S:344 E:349 ||| CC
during  ||| S:349 E:356 ||| IN
and  ||| S:356 E:360 ||| CC
after  ||| S:360 E:366 ||| IN
its  ||| S:366 E:370 ||| PRP$
performance ||| S:370 E:381 ||| NN
,  ||| S:381 E:383 ||| ,
and  ||| S:383 E:387 ||| CC
thus  ||| S:387 E:392 ||| RB
to  ||| S:392 E:395 ||| TO
reduce  ||| S:395 E:402 ||| VB
the  ||| S:402 E:406 ||| DT
direct  ||| S:406 E:413 ||| JJ
and  ||| S:413 E:417 ||| CC
indirect  ||| S:417 E:426 ||| JJ
costs  ||| S:426 E:432 ||| NNS
of  ||| S:432 E:435 ||| IN
allergic  ||| S:435 E:444 ||| JJ
rhinitis  ||| S:444 E:453 ||| NN
and  ||| S:453 E:457 ||| CC
asthma ||| S:457 E:463 ||| NN
.  ||| S:463 E:465 ||| .
A  ||| S:465 E:467 ||| DT
number  ||| S:467 E:474 ||| NN
of  ||| S:474 E:477 ||| IN
studies  ||| S:477 E:485 ||| NNS
reported  ||| S:485 E:494 ||| VBD
a  ||| S:494 E:496 ||| DT
cost  ||| S:496 E:501 ||| NN
reduction  ||| S:501 E:511 ||| NN
for  ||| S:511 E:515 ||| IN
traditional ||| S:515 E:526 ||| JJ
,  ||| S:526 E:528 ||| ,
subcutaneous  ||| S:528 E:541 ||| VBD
IT  ||| S:541 E:544 ||| PRP
( ||| S:544 E:545 ||| -LRB-
SCIT ||| S:545 E:549 ||| NNP
) ||| S:549 E:550 ||| -RRB-
.  ||| S:550 E:552 ||| .
We  ||| S:552 E:555 ||| PRP
analyzed  ||| S:555 E:564 ||| VBD
the  ||| S:564 E:568 ||| DT
available  ||| S:568 E:578 ||| JJ
studies  ||| S:578 E:586 ||| NNS
on  ||| S:586 E:589 ||| IN
economic  ||| S:589 E:598 ||| JJ
evaluation  ||| S:598 E:609 ||| NN
of  ||| S:609 E:612 ||| IN
sublingual  ||| S:612 E:623 ||| JJ
immunotherapy  ||| S:623 E:637 ||| NNS
( ||| S:637 E:638 ||| -LRB-
SLIT ||| S:638 E:642 ||| NNP
)  ||| S:642 E:644 ||| -RRB-
in  ||| S:644 E:647 ||| IN
children  ||| S:647 E:656 ||| NNS
and  ||| S:656 E:660 ||| CC
adults ||| S:660 E:666 ||| NNS
.  ||| S:666 E:668 ||| .
Articles  ||| S:668 E:677 ||| NNS
were  ||| S:677 E:682 ||| VBD
retrieved  ||| S:682 E:692 ||| VBN
from  ||| S:692 E:697 ||| IN
Medline  ||| S:697 E:705 ||| NNP
and  ||| S:705 E:709 ||| CC
Embase  ||| S:709 E:716 ||| NNP
using  ||| S:716 E:722 ||| VBG
the  ||| S:722 E:726 ||| DT
terms  ||| S:726 E:732 ||| NNS
economic  ||| S:732 E:741 ||| JJ
aspects ||| S:741 E:748 ||| NNS
,  ||| S:748 E:750 ||| ,
pharmacoeconomics ||| S:750 E:767 ||| NN
,  ||| S:767 E:769 ||| ,
cost  ||| S:769 E:774 ||| NN
effectiveness ||| S:774 E:787 ||| NN
,  ||| S:787 E:789 ||| ,
and  ||| S:789 E:793 ||| CC
sublingual  ||| S:793 E:804 ||| CD
immunotherapy.  ||| S:804 E:819 ||| CD
18  ||| S:819 E:822 ||| CD
articles  ||| S:822 E:831 ||| NNS
were  ||| S:831 E:836 ||| VBD
found  ||| S:836 E:842 ||| VBN
in  ||| S:842 E:845 ||| IN
English  ||| S:845 E:853 ||| JJ
language ||| S:853 E:861 ||| NN
,  ||| S:861 E:863 ||| ,
7  ||| S:863 E:865 ||| CD
studies  ||| S:865 E:873 ||| NNS
investigated  ||| S:873 E:886 ||| VBD
the  ||| S:886 E:890 ||| DT
economic  ||| S:890 E:899 ||| JJ
advantage  ||| S:899 E:909 ||| NN
of  ||| S:909 E:912 ||| IN
SLIT  ||| S:912 E:917 ||| NNP
over  ||| S:917 E:922 ||| IN
standard  ||| S:922 E:931 ||| JJ
drug  ||| S:931 E:936 ||| NN
treatment  ||| S:936 E:946 ||| NN
in  ||| S:946 E:949 ||| IN
subjects  ||| S:949 E:958 ||| NNS
with  ||| S:958 E:963 ||| IN
respiratory  ||| S:963 E:975 ||| JJ
allergy ||| S:975 E:982 ||| NN
,  ||| S:982 E:984 ||| ,
and  ||| S:984 E:988 ||| CC
2  ||| S:988 E:990 ||| CD
of  ||| S:990 E:993 ||| IN
them  ||| S:993 E:998 ||| PRP
included  ||| S:998 E:1007 ||| VBD
a  ||| S:1007 E:1009 ||| DT
comparison  ||| S:1009 E:1020 ||| NN
of  ||| S:1020 E:1023 ||| IN
costs  ||| S:1023 E:1029 ||| NNS
of  ||| S:1029 E:1032 ||| IN
SCIT  ||| S:1032 E:1037 ||| NNP
and  ||| S:1037 E:1041 ||| CC
SLIT ||| S:1041 E:1045 ||| NNP
.  ||| S:1045 E:1047 ||| .
The  ||| S:1047 E:1051 ||| DT
data  ||| S:1051 E:1056 ||| NNS
obtained  ||| S:1056 E:1065 ||| VBD
provide  ||| S:1065 E:1073 ||| VB
evidence  ||| S:1073 E:1082 ||| NN
that  ||| S:1082 E:1087 ||| IN
SLIT  ||| S:1087 E:1092 ||| NNP
is  ||| S:1092 E:1095 ||| VBZ
associated  ||| S:1095 E:1106 ||| VBN
to  ||| S:1106 E:1109 ||| TO
economic  ||| S:1109 E:1118 ||| JJ
advantages  ||| S:1118 E:1129 ||| NNS
and ||| S:1129 E:1132 ||| CC
/ ||| S:1132 E:1133 ||| NNP
or  ||| S:1133 E:1136 ||| CC
monetary  ||| S:1136 E:1145 ||| JJ
savings ||| S:1145 E:1152 ||| NNS
,  ||| S:1152 E:1154 ||| ,
specifically  ||| S:1154 E:1167 ||| RB
in  ||| S:1167 E:1170 ||| IN
terms  ||| S:1170 E:1176 ||| NNS
of  ||| S:1176 E:1179 ||| IN
reduction  ||| S:1179 E:1189 ||| NN
of  ||| S:1189 E:1192 ||| IN
economic  ||| S:1192 E:1201 ||| JJ
burden  ||| S:1201 E:1208 ||| NN
of  ||| S:1208 E:1211 ||| IN
the  ||| S:1211 E:1215 ||| DT
disease ||| S:1215 E:1222 ||| NN
.  ||| S:1222 E:1224 ||| .
Although  ||| S:1224 E:1233 ||| IN
the  ||| S:1233 E:1237 ||| DT
number  ||| S:1237 E:1244 ||| NN
of  ||| S:1244 E:1247 ||| IN
studies  ||| S:1247 E:1255 ||| NNS
is  ||| S:1255 E:1258 ||| VBZ
still  ||| S:1258 E:1264 ||| RB
limited ||| S:1264 E:1271 ||| VBN
,  ||| S:1271 E:1273 ||| ,
the  ||| S:1273 E:1277 ||| DT
available  ||| S:1277 E:1287 ||| JJ
data  ||| S:1287 E:1292 ||| NNS
support  ||| S:1292 E:1300 ||| VBP
a  ||| S:1300 E:1302 ||| DT
SLIT  ||| S:1302 E:1307 ||| NNP
effect  ||| S:1307 E:1314 ||| NN
on  ||| S:1314 E:1317 ||| IN
sparing  ||| S:1317 E:1325 ||| JJ
costs  ||| S:1325 E:1331 ||| NNS
for  ||| S:1331 E:1335 ||| IN
respiratory  ||| S:1335 E:1347 ||| JJ
allergy ||| S:1347 E:1354 ||| NN
.  ||| S:1354 E:1356 ||| .
